Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Paoletti

Showing results (71-80 of 145) with videos related to

Pageof 15
Sort By:
Investigational New Drugs|October 28, 2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancerChristian Dittrich, Veronique Dieras, Pierre Kerbrat, et al.
Future Oncology (London, England)|February 5, 2021
Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysisMathieu Roumiguié, Xavier Paoletti, Yann Neuzillet, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 12, 2008
Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trialsFranck Bonnetain, Xavier Paoletti, Sandra Collette, et al.
Intensive Care Medicine|July 2, 2005
Successful long-term program for controlling methicillin-resistant Staphylococcus aureus in intensive care unitsJean-Christophe Lucet, Xavier Paoletti, Isabelle Lolom, et al.
ESMO Open|August 2, 2017
Patient-reported tolerability of adverse events in phase 1 trialsClémence Henon, Delphine Lissa, Xavier Paoletti, et al.
Personalized Medicine|May 16, 2018
Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trialsLoic Verlingue, Marie Alt, Maud Kamal, et al.
Archives of Internal Medicine|August 12, 2009
Carriage of methicillin-resistant Staphylococcus aureus in home care settings: prevalence, duration, and transmission to household membersJean-Christophe Lucet, Xavier Paoletti, Christine Demontpion, et al.
Critical Care Medicine|June 9, 2005
Regulation of peritoneal and systemic neutrophil-derived tumor necrosis factor-alpha release in patients with severe peritonitis: role of tumor necrosis factor-alpha converting enzyme cleavageNathalie Kermarrec, Saphia Selloum, Gaetan Plantefeve, et al.
Oncotarget|September 23, 2016
Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trialEmilie Desportes, Mathilde Wagner, Maud Kamal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?Sophie Postel-Vinay, Carlos Gomez-Roca, L Rhoda Molife, et al.
Pageof 15

Showing results (71-80 of 145) with videos related to

Sort By:
Pageof 15
Investigational New Drugs|October 28, 2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancerChristian Dittrich, Veronique Dieras, Pierre Kerbrat, et al.
Future Oncology (London, England)|February 5, 2021
Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysisMathieu Roumiguié, Xavier Paoletti, Yann Neuzillet, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 12, 2008
Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trialsFranck Bonnetain, Xavier Paoletti, Sandra Collette, et al.
Intensive Care Medicine|July 2, 2005
Successful long-term program for controlling methicillin-resistant Staphylococcus aureus in intensive care unitsJean-Christophe Lucet, Xavier Paoletti, Isabelle Lolom, et al.
ESMO Open|August 2, 2017
Patient-reported tolerability of adverse events in phase 1 trialsClémence Henon, Delphine Lissa, Xavier Paoletti, et al.
Personalized Medicine|May 16, 2018
Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trialsLoic Verlingue, Marie Alt, Maud Kamal, et al.
Archives of Internal Medicine|August 12, 2009
Carriage of methicillin-resistant Staphylococcus aureus in home care settings: prevalence, duration, and transmission to household membersJean-Christophe Lucet, Xavier Paoletti, Christine Demontpion, et al.
Critical Care Medicine|June 9, 2005
Regulation of peritoneal and systemic neutrophil-derived tumor necrosis factor-alpha release in patients with severe peritonitis: role of tumor necrosis factor-alpha converting enzyme cleavageNathalie Kermarrec, Saphia Selloum, Gaetan Plantefeve, et al.
Oncotarget|September 23, 2016
Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trialEmilie Desportes, Mathilde Wagner, Maud Kamal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?Sophie Postel-Vinay, Carlos Gomez-Roca, L Rhoda Molife, et al.
Pageof 15